| Synonyms: | |
| Status: | Phase 2 |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| UNII: | 6FHZ595FNM |
Physicochemical Descriptors
| Property Name | Value |
|---|---|
| Molecular Formula | C30H30FN5O3 |
| Molecular Weight | 527.6 |
| AlogP | 4.46 |
| Hydrogen Bond Acceptor | 5.0 |
| Hydrogen Bond Donor | 2.0 |
| Number of Rotational Bond | 4.0 |
| Polar Surface Area | 97.87 |
| Molecular species | None |
| Aromatic Rings | 4.0 |
| Heavy Atoms | 39.0 |
Pharmacology
| Action | Mechanism of Action | Reference |
|---|---|---|
| ANTAGONIST | Mineralocorticoid receptor antagonist |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Transcription factor
Nuclear receptor
Nuclear hormone receptor subfamily 3
Nuclear hormone receptor subfamily 3 group C
Nuclear hormone receptor subfamily 3 group C member 2
|
- | - | - | 0.33 | - |
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Renal Insufficiency, Chronic | 2 | D051436 | ClinicalTrials |
| Essential Hypertension | 2 | D000075222 | ClinicalTrials |
Cross References
| Resources | Reference |
|---|---|
| ChEMBL | CHEMBL3545275 |
| FDA SRS | 6FHZ595FNM |
CONTENTS